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Abstract
Background: Strong longitudinal evidence exists that psychological distress is associated with a high morbidity
and mortality risk in type 2 diabetes. Little is known about the biological and behavioral mechanisms that may
explain this association. Moreover, the role of personality traits in these associations is still unclear. In this paper, we
first describe the design of the psychological part of The Maastricht Study that aims to elucidate these mechanisms.
Next, we present exploratory results on the prevalence of depression, anxiety and personality traits in type 2
diabetes. Finally, we briefly discuss the importance of these findings for clinical research and practice.
Methods: We measured psychological distress and depression using the MINI diagnostic interview, the PHQ-9 and
GAD-7 questionnaires in the first 864 participants of The Maastricht Study, a large, population-based cohort study.
Personality traits were measured by the DS14 and Big Five personality questionnaires. Type 2 diabetes was assessed
by an oral glucose tolerance test. Logistic regression analyses were used to estimate the associations of depression,
anxiety and personality with type 2 diabetes, adjusted for age, sex and education level.
Results: Individuals with type 2 diabetes had higher levels of depressive and anxiety symptoms, odds ratios (95 %
CI) were 3.15 (1.49; 6.67), 1.73 (0.83–3.60), 1.50 (0.72–3.12), for PHQ-9 ≥ 10, current depressive disorder and GAD-7 ≥
10, respectively. Type D personality, social inhibition and negative affectivity were more prevalent in type 2
diabetes, odds ratios were 1.95 (1.23–3.10), 1.35 (0.93–1.94) and 1.70 (1.14–2.51), respectively. Individuals with type 2
diabetes were less extraverted, less conscientious, less agreeable and less emotionally stable, and similar in
openness to individuals without type 2 diabetes, although effect sizes were small.
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Conclusions: Individuals with type 2 diabetes experience more psychological distress and have different personality
traits compared to individuals without type 2 diabetes. Future longitudinal analyses within The Maastricht Study will
increase our understanding of biological and behavioral mechanisms that link psychological distress to morbidity
and mortality in type 2 diabetes.
Keywords: Type 2 diabetes, Cohort, Design, Exploratory results, Depression, Anxiety, Personality
Background
Type 2 diabetes mellitus is an increasingly common
chronic disease, afflicting an estimated 171 million indi-
viduals with type 2 diabetes in 2000 to 366 million in
2030 [1]. Individuals with type 2 diabetes are at higher
risk to develop micro- and macrovascular complications
and have higher mortality rates [2, 3]. Depression is a
frequent co-morbid condition in individuals with type 2
diabetes. Two meta-analyses report that depression is al-
most twice as common in type 2 diabetes compared to
individuals without diabetes [4, 5]. In addition, depres-
sive symptoms appeared to be highly persistent and/or
recurrent in type 2 diabetes. For example, Nefs et al. [6]
showed that 66 % of individuals with type 2 diabetes
who had a high depression score, still had a high score
two to three years later. Furthermore, multiple studies
have linked depression to a variety of adverse health out-
comes among individuals with type 2 diabetes, like a re-
duced quality of life [7], less optimal self-care behaviors
and higher HbA1c levels [8], a higher risk of micro- and
macrovascular complications [9], higher mortality rates
[10] and increased health care costs [11]. However, the
majority of these studies had a cross-sectional design,
thereby limiting the possibility to assess the temporal se-
quence of the observed associations.
In contrast, little is known about the risk of other
forms of distress, for example those that are related
to anxiety. Anxiety frequently co-occurs with depres-
sive symptoms [12, 13], and therefore appears to be
common in type 2 diabetes. Similar to depression,
anxiety disorders typically have a chronic and recur-
rent life course, and elevated anxiety symptoms and
diagnosed anxiety disorders in type 2 diabetes have
been associated with reduced quality of life [14], poor
glycemic control [15, 16] and diabetes complications
[17]. Yet, the association between type 2 diabetes and
anxiety has not been studied extensively. The mecha-
nisms underlying this association may show similar-
ities with those of depression as anxiety is associated
with deregulation of the hypothalamic-pituitary-
adrenal (HPA) axis [18], but also life-style factors
such as dietary behavior, physical inactivity and obes-
ity may be relevant [19].
In addition to psychological variables, personality
factors emerge as potential vulnerability factor for
adverse health outcomes. Type D personality refers to
the combination of negative affectivity (tendency to
experience negative emotions) and social inhibition
(tendency to inhibit self-expression) [20]. The Type D
or ‘distressed’ personality has been related to poor
health status, morbidity and mortality in cardiovascu-
lar disease [21–23], although negative findings have
also been reported [24, 25]. One potential mechanism
through which Type D may exert a negative influence
on health is suboptimal self-care behavior. Also, bio-
logical mechanisms like a dysfunctional HPA-axis, in-
creased heart rate and blood pressure have been
proposed [26–29]. Nonetheless, to our knowledge few
studies have explored the potential behavioral and
biological mechanisms that may link Type D with ad-
verse health outcomes in individuals with type 2 dia-
betes [30].
Prospective detailed longitudinal studies combining
extensive phenotyping on depression, anxiety and type
2 diabetes with a focus on a broad range of determi-
nants are needed to elucidate the complex underlying
pathophysiology between depression, type 2 diabetes
and adverse health outcomes. The Maastricht Study
has been designed as a large, prospective population-
based cohort study that fits these needs. The niche of
this study lies in the advanced assessment of both de-
pression and type 2 diabetes, but also in the vast
number of participants of the study, as we aim to in-
clude 10,000 participants with substantial oversam-
pling of individuals with type 2 diabetes. To our
knowledge, The Maastricht Study is the first attempt
to address the different mechanisms underlying the
complex association of depression and type 2 diabetes
comprehensively in one population.
The main aim of the current paper is to describe the
psychological design and research questions within the
framework of The Maastricht Study, which amongst
others, focuses on psychological variables and personal-
ity in the context of type 2 diabetes. In addition, we also
present the findings of psychological and personality as-
sessments in the first 862 participants of The Maastricht
Study to document the feasibility of these assessments in
this study. We will conclude with theories on possible
mechanisms linking psychological distress with type 2
diabetes, and with suggestions for future research.
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Methods
The Maastricht Study
Study design, subject eligibility and recruitment
The Maastricht Study is an observational prospective
population-based cohort study, enriched with type 2 dia-
betes individuals. The rationale and methodology have
been described previously [31]. In brief, the study fo-
cuses on the etiology, pathophysiology, complications
and comorbidities of type 2 diabetes and is characterized
by an extensive phenotyping approach. The study popu-
lation will be enriched with type 2 diabetes participants
for reasons of efficiency; i.e., to increase the statistical
power to identify any potential contrasts between indi-
viduals with and without type 2 diabetes.
Eligible for participation were all individuals aged be-
tween 40 and 75 years and living in the southern part of
the Netherlands. Participants were recruited through
mass media campaigns and from the municipal registries
and the regional Diabetes Patient Registry via mailings.
The regional Diabetes Patient Registry is kept by the re-
gional association of General Practitioners and the
Maastricht University Medical Centre. This registry in-
cludes individuals that apply to their general practitioner
with health complaints which lead to the diagnosis of
type 2 diabetes, and individuals that are diagnosed with
type 2 diabetes after cardiovascular screening. The regis-
try virtually includes all individuals with type 2 diabetes
in primary, secondary or tertiary medical care in the
“Maastricht and Heuvelland” region.
Recruitment was stratified according to known type 2
diabetes status for reasons of efficiency. The present re-
port includes cross-sectional data from the first 866 par-
ticipants, who completed the baseline survey between
November 2010 and March 2012. The examinations of
each participant were performed and completed within a
time window of 3 months. The study has been approved
by the institutional medical ethical committee (Medisch
Ethische Commissie aZM/UM, (NL31329.068.10) and
the Netherlands Health Council under the Dutch “Law
for Population Studies” (Permit 131088-105234-PG). All
participants gave written informed consent.
Research questions
To further increase our understanding of the association
between psychosocial variables and adverse health out-
comes in type 2 diabetes, we aim to address the follow-
ing research questions within the framework of The
Maastricht Study:
1) What is the effect of type 2 diabetes on the
development and recurrence of depression?
2) What is the effect of depression on the development
and progression of type 2 diabetes? In particular
impaired glucose metabolism, micro- and
macrovascular complications, mortality and, quality
of life will be evaluated.
3) What mechanisms may explain these associations,
with a specific focus on psychosocial (e.g. burden of
disease, anxiety or personality traits), biological (e.g.
vascular factors, inflammation, hyperglycemia,
deregulated HPA-axis) and behavioral (e.g. physical
inactivity, poor diet, smoking) mechanisms?
4) What is the potential added value (additional
variance explained), of anxiety and personality in the
association of psychological variables with type 2
diabetes?
In this paper we did not address these research ques-
tions, as we present a descriptive study with exploratory
first results of The Maastricht Study.
Diagnosis of diabetes
To determine glucose metabolism, all participants (ex-
cept those who use insulin) underwent a standardized 7-
point oral glucose tolerance test (OGTT) after an over-
night fast. Blood samples are taken at baseline, and 15,
30, 45, 60, 90 and 120 min after ingestion of a 75 g glu-
cose drink. For safety reasons, participants with a fasting
glucose level above 11.0 mmol/l, as determined by a fin-
ger prick, did not undergo the OGTT. Glucose metabol-
ism is defined according to the WHO 2006 criteria into
normal glucose tolerance (NGT), impaired fasting glu-
cose (IFG), impaired glucose tolerance (IGT) and type 2
diabetes [32]. These criteria maintain the following
thresholds; for NGT fasting plasma glucose level of ≤
6.0 mmol/L, for IFG fasting plasma glucose level of 6.1–
6.9 mmol/L and a 2-h plasma glucose of < 7.8 mmol/L,
for IGT fasting plasma glucose of <7.0 mmol/L and a 2-
h plasma glucose of ≥ 7.8 and ≤ 11.1 mmol/L, for type 2
diabetes fasting plasma glucose of ≥ 7.0 mmol/L or a 2-h
plasma glucose of ≥ 11.1 mmol/L. Individuals that used
glucose-lowering medication were classified as having
type 2 diabetes. Individuals with type 1 diabetes (n = 4),
were excluded from the analyses.
Diagnosis of depression and anxiety disorder
The Mini-International Neuropsychiatric Interview
(MINI) [33] was used to determine whether participants
suffered from an anxiety disorder or a depressive dis-
order. The MINI is a short diagnostic structured inter-
view, used to assess the presence of minor or major
depressive disorder, or an anxiety disorder in the preced-
ing 2 weeks and in the past (lifetime depression) accord-
ing to the DSM-IV. The MINI includes questions about
age at onset of first depressive episode and number of
episodes, and was administered by four trained investi-
gators. The following DMS-IV classifications were
distinguished: depressive disorder (major and minor
van Dooren et al. BMC Psychiatry  (2016) 16:17 Page 3 of 11
depression), lifetime (recurrent) depressive episode and
dysthymia. Participants were diagnosed as having a de-
pressive disorder if they had at least one core symptom
(i.e. depressed mood or loss of interest) and at least one
other symptom of depression (minor depression), or at
least one core symptom (i.e. depressed mood or loss of
interest) and at least four other symptoms of depression
(major depression in DSM-IV). If a person suffers from
two or more of these episodes in his or her life, a diag-
nosis of lifetime (recurrent) depression was made. Dys-
thymia represents a longer-lasting but symptomatically
milder disorder, defined by at least two years of contin-
ued mood disturbance, along with at least two associated
symptoms.
The MINI was also used to assess the presence of
panic disorder, agoraphobia and social phobia, according
to the DSM-IV criteria. With regard to panic disorder
assessed by means of the MINI, four screening questions
were applied to rule out the diagnosis when answered
negatively. With use of decision tree logic, positive re-
sponses to screening questions are explored by further
investigation of other diagnostic criteria. Participants
were diagnosed with panic disorder if they answered all
screening questions positively, and had at least four
symptoms of panic disorder. For a diagnosis of agora-
phobia and social phobia all screening questions had to
be answered affirmatively.
Symptoms of depression and anxiety
Depressive symptoms were assessed by a validated
Dutch version of the 9-item Patient Health Question-
naire (PHQ-9) [34]. The PHQ-9 is a self-administered
questionnaire based on the DMS-IV (Diagnostic and
Statistical Manual of Mental Disorders, Fourth Edi-
tion) [35] criteria for a major depressive disorder. It
comprises nine items rated on a 4-point scale, ran-
ging from 0 = “not at all” to 3 = “nearly every day”.
Response options can generate a continuous score
ranging from 0 (no symptoms) to 27 (all symptoms
present nearly every day); scores 10–14 represent
moderate and 15–27 moderately severe to severe de-
pression symptoms. The PHQ-9 scale was also used
as a dichotomous variable with a pre-defined cut-off
level of 10, which represents the presence of clinically
relevant depressive symptoms.
Anxiety symptoms were assessed by a validated Dutch
version of the 7-item Generalized Anxiety Disorder scale
(GAD-7) [36]. The GAD-7 is a self-administered
questionnaire based on the DMS-IV criteria for a gener-
alized anxiety disorder (GAD). It comprises seven items
rated on a 4-point scale, ranging from 0 = “not at all” to
3 = “nearly every day”. Total scores range from 0 to 21,
with higher scores indicating the presence of more (se-
vere) anxiety symptoms. The GAD-7 can be used both
as a continuous score, with minimal (0–4), mild (5–9),
moderate (10–14) and severe (15–21) symptoms, as well
as a dichotomous variable, with a pre-defined cut-off of
10, which represents a probable diagnosis of GAD. Both
questionnaires have been used in other studies on dia-
betes [37–40].
Personality traits
Personality traits were assessed by a validated Dutch ver-
sion of the Type D Scale-14 (DS14) [20] and the Quick
Big Five [41]. The DS14 assesses Type D personality,
which is characterized by negative affectivity, the ten-
dency to experience negative emotions across time/situ-
ations, and social inhibition, the tendency to inhibit the
expression of emotions in social interactions to avoid
disapproval. The DS14 comprises 14 items, which are
scored on a 5-point rating scale ranging from 0 = “false”
to 4 = “true”, and uses two subscales, measuring level of
negative affectivity and social inhibition. Total scores on
both subscales range from 0 to 28. The DS-14 is used as
a dichotomous score, with subjects obtaining a score
of ≥ 10 on both subscales are considered to have a Type
D personality. Previously, the DS14 has also been vali-
dated in primary care patients with type 2 diabetes [30].
The Quick Big Five is a Dutch, shortened version of
the Big Five Factor Structure developed by Goldberg et
al. [42]. The Quick Big Five measures five main
personality domains; extraversion, agreeableness, con-
scientiousness, emotional stability and openness to ex-
perience, with 6-items assigned for each domain. This
questionnaire consists of 30 items, which are scored on
a 7-point rating scale ranging from 1 = “very inaccurate”
to 7 = “very accurate”. Total scores for each personality
trait range from 6 to 42. All main personality traits are
named according to the ‘high scoring’ end of each scale.
Higher scores on each trait indicate a strong presence of
this personality trait and affiliated behaviors, and will be
less able to sustain the tendencies of the low scorer, and
vice versa. Both questionnaires on personality have been
used in previous research on diabetes [30, 43].
Sociodemographic and clinical characteristics
As previously described [31, 44] diabetes duration, part-
ner status, socioeconomic status based on education
level and smoking status were assessed by self-report
questionnaire. Educational level was assessed during a
cognitive assessment interview and was classified into
eight categories commonly used in The Netherlands
[45]: 1) no education; 2) primary education; 3) lower
vocational education; 4) intermediate general secondary
education; 5) intermediate vocational education; 6)
higher general secondary education; 7) higher vocational
education; and 8) university. For this study, three groups
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were created for educational level: low (levels 1–3), mid-
dle (levels 4–6) and high (levels 7 and 8).
Smoking behavior was based on self-report of
smoking cigarettes, cigars and/or pipe tobacco and di-
vided into three categories, i.e. non-smoker, former
smoker and current smoker. Additionally, lifetime
smoking was expressed as pack-years; one pack-year
was defined as one packet (=20 cigarettes) per day,
smoked over a course of 1 year. Fasting venous blood
samples were used to assess glucose levels, HbA1c
and lipid profile. Medication use was assessed by
interview. Height and weight were measured to calcu-
late body mass index. Office blood pressure was mea-
sured three times after 10 min of seated rest, and the
mean of these three measurements was used for
analyses.
Statistical analyses
Statistical analyses were performed with SPSS 20 for
Windows. Four participants with type 1 diabetes were
excluded from the analyses. Comparisons of sociode-
mograpic and clinical characteristics, depression, anx-
iety and personality traits between individuals with
and without type 2 diabetes were made by use of in-
dependent sample t-tests or Chi-square tests. We
used logistic regression analyses to estimate the asso-
ciations of depression, anxiety and personality traits
with type 2 diabetes (outcome variable) adjusted for
age, sex and education level.
Results
Sociodemographic and clinical characteristics
Sociodemographic and clinical characteristics of the
first 862 participants of The Maastricht Study are
presented in Table 1 according to type 2 diabetes sta-
tus. Individuals with type 2 diabetes were older, more
frequently male and had a lower educational level as
compared to individuals without type 2 diabetes. As
expected, HbA1c levels were higher in type 2 dia-
betes, as were body mass index, systolic and diastolic
blood pressure as compared to individuals without
type 2 diabetes. Individuals with type 2 diabetes had a
favorable lipid profile, which is probably due to the
high frequency of lipid-lowering medication use in
type 2 diabetes.
Data on depression, anxiety and personality traits were
available in n = 852 for the MINI interview, n = 757 for
PHQ-9, n = 721 for GAD-7, n = 712 for type D personal-
ity, n = 712 for Big Five personality traits. Missing data
were mainly due to not completing the questionnaires.
Prevalence of psychological distress and personality traits
in type 2 diabetes
Table 2 shows the prevalence of depressive and anx-
iety symptoms and personality traits in relation to
type 2 diabetes. A statistically significantly higher
level of depressive symptoms was found in type 2 dia-
betes as measured by the PHQ-9. This difference was
less pronounced for depressive disorder assessed by
the MINI, and absent for lifetime depressive episode.
Table 1 Sociodemographic and clinical characteristics of The Maastricht Study participants
No type 2 diabetes (n = 609) Type 2 diabetes (n = 253) p-value
Age, years 58 ± 8.6 64 ± 7.0 < 0.001
Male sex, n (%) 296 (49 %) 176 (70 %) < 0.001
Partner, n (%) 515 (85 %) 208 (85 %) 0.98
Educational level, % low/middle/high 12/39/49 28/47/25 <0.001
HbA1c, % 5.65 ± 0.37 6.91 ± 0.88 < 0.001
Diabetes duration, years - 7 [3–11]
Diabetes medication, % no/oral/insulin - 22/57/21
Smoking, % never/former/current 34/49/17 22/64/14
Pack years 4 [0–18] 15 [0–33] < 0.001
Body mass index, kg/m2 26.3 ± 4.0 29.8 ± 4.7 < 0.001
Systolic blood pressure, mmHg 133 ± 18 146 ± 19 < 0.001
Diastolic blood pressure, mmHg 76 ± 10 78 ± 10 0.004
Total cholesterol, mmol/l 5.5 ± 1.1 4.4 ± 1.0 < 0.001
HDL cholesterol, mmol/l 1.40 ± 0.41 1.12 ± 0.40 < 0.001
LDL cholesterol, mmol/l 3.5 ± 1.0 2.6 ± 0.9 < 0.001
Triglycerides, mmol/l 1.3 ± 0.9 1.8 ± 1.0 < 0.001
Data are presented as mean ± standard deviation (SD), number (percentage) or as median [inter quartile range (IQR)], unless otherwise indicated
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Dysthymia was more prevalent in type 2 diabetes,
though the numbers in both groups were small. Anx-
iety symptoms were not significantly different in indi-
viduals with and without type 2 diabetes. Anxiety
disorders as assessed by the MINI had a low preva-
lence, therefore, formal testing of differences was only
possible for agoraphobia. Current agoraphobia was
somewhat more prevalent in individuals with type 2
diabetes, while the prevalence of panic disorder and
social phobia were similar between groups. Type D
personality was statistically significantly associated
with type 2 diabetes, as were its two constituting
components ‘social inhibition’ and ‘negative affectivity’.
The Big Five showed statistically significantly lower
levels in type 2 diabetes for the personality traits
‘extraversion’, ‘agreeableness’, ‘conscientiousness’ and
‘emotional stability’, yet ‘openness to experience’ was
not different between individuals with and without
type 2 diabetes.
Association of type 2 diabetes with psychological distress
and personality traits
In Table 3, logistic regression analyses adjusted for age,
sex and education level showed a 10 % higher odds of
having type 2 diabetes per point increase in PHQ-9
score, while a PHQ-9 level ≥10 was associated with a
3.15 times higher odds. Depressive disorder was not sta-
tistically significant associated with type 2 diabetes. With
regard to anxiety, logistic regression analyses adjusted
for age, sex and education level showed no statistically
significant association with type 2 diabetes. For Type D
personality, logistic regression analyses showed a 95 %
higher odds for type 2 diabetes, while a slightly reduced
odds of type 2 diabetes ranging between 3 and 6 % was
Table 2 Prevalence of depressive and anxiety symptoms and personality traits in individuals with/ without type 2 diabetes
No type 2 diabetes Type 2 diabetes p-value
Depressive symptoms
PHQ-9 score 2.46 ± 3.18 3.26 ± 4.53 0.020
PHQ-9≥ 10 23 (4.2 %) 16 (7.8 %) 0.081
Depressive disorder
Depressive disorder (MINI) 33 (5.5 %) 22 (8.8 %) 0.105
Lifetime depressive episode (MINI) 220 (36.5 %) 86 (34.3 %) 0.538
Dysthymia (MINI) 5 (0.8 %) 7 (2.8 %) a
Anxiety symptoms
GAD-7 score 2.59 ± 3.59 2.83 ± 4.01 0.444
GAD-7≥ 10 29 (5.4 %) 14 (7 %) 0.424
Anxiety disorders
Current panic disorder 4 (0.7 %) 3 (1.2 %) a
Lifetime panic disorder 26 (4.3 %) 6 (2.4 %) a
Current agoraphobia 35 (5.8 %) 24 (9.6 %) 0.073
Current social phobia 9 (1.5 %) 3 (1.2 %) a
Type D personality
Social inhibition 8.55 ± 4.63 9.62 ± 5.27 0.013
Social inhibition score≥ 10 189 (36.4 %) 87 (45.1 %) 0.038
Negative affectivity 7.47 ± 4.93 8.54 ± 5.65 0.020
Negative affectivity score≥ 10 140 (27 %) 70 (36.3 %) 0.020
Type D personality 79 (15.2 %) 44 (22.8 %) 0.027
Big Five personality traits
Extraversion 30.4 ± 6.5 28.9 ± 7.4 0.016
Agreeableness 34.8 ± 3.7 33.7 ± 4.8 0.004
Conscientiousness 32.6 ± 5.7 31.1 ± 5.9 0.002
Emotional stability 30.6 ± 6.3 29.5 ± 7.0 0.058
Openness 28.5 ± 6.5 28.0 ± 6.4 0.287
Data are presented as mean ± standard deviation or number (percentage)
a Formal testing was not possible due low numbers
Bold data reflect significant findings
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observed for the various personality traits of the Big
Five.
Discussion
Our first exploratory results indicate a higher prevalence
of both depressive and anxiety symptoms in type 2 dia-
betes. This is in line with previous studies [46, 47]. A
similar trend was observed for depressive disorder, with
a higher prevalence in type 2 diabetes, although the dif-
ference was not statistically significant. In addition, Type
D personality was more prevalent in type 2 diabetes,
while personality traits like extraversion, agreeableness,
consciousness and emotional stability were slightly less
prevalent.
There are a number of possible mechanisms that may
explain the link between type 2 diabetes and psycho-
logical distress. Below, we will discuss a number of these
mechanisms, with a particular focus on depression.
Psychosocial mechanisms
The “psychological burden hypothesis” states that the
burden of knowing that one has diabetes, the manage-
ment of having a chronic illness, or having
complications to cope with, contribute to higher levels
of depression [48]. In line with this hypothesis, a meta-
analysis showed that the occurrence of depression was
particularly increased in known type 2 diabetes, but not
in persons with screen-detected type 2 diabetes (who
were unaware that they had diabetes), or those with im-
paired glucose metabolism [49]. Type 2 diabetes self-
management is known to be burdensome, as it requires
discipline and perseverance to adapt every day activities
(diet, exercise, rest) to medication use and glucose levels
[50]. Insulin therapy, particularly, may be associated with
increased psychological distress [51]. Moreover, diabetes
complications can cause functional limitations (reduced
mobility, visual impairments, fatigue, pain) and a re-
duced quality of life [52]. In the Longitudinal Aging
Study Amsterdam (LASA), depressive symptoms were
particularly common in individuals with type 2 diabetes
and comorbid diseases, and not in individuals with type
2 diabetes alone [53].
Biological mechanisms
Several biological mechanisms have been suggested to
underlie the association between psychological distress
Table 3 The association of depression and anxiety symptoms and personality traits with type 2 diabetes, adjusted for age, sex and
education level
Type 2 diabetes versus no diabetes
Odds ratioa (95 % CI) p-value
Depressive symptoms
PHQ-9 score 1.10 (1.05–1.15) <0.001
PHQ-9≥ 10 3.15 (1.49–6.67) 0.003
Depressive disorder
Depressive disorder (MINI) 1.73 (0.83–3.60) 0.156
Lifetime depressive episode (MINI) 0.97 (0.69–1.36) 0.862
Anxiety symptoms
GAD-7 score 1.03 (0.99–1.08) 0.162
GAD-7≥ 10 1.50 (0.72–3.12) 0.280
Type D personality
Social inhibition 1.04 (1.00–1.08) 0.032
Social inhibition score≥ 10 1.35 (0.93–1.94) 0.112
Negative affectivity 1.05 (1.02–1.09) 0.004
Negative affectivity score≥ 10 1.70 (1.14–2.51) 0.009
Type D personality 1.95 (1.23–3.10) 0.005
Big Five personality traits
Extraversion 0.97 (0.95–1.00) 0.023
Agreeableness 0.94 (0.90–0.98) 0.003
Conscientiousness 0.94 (0.91–0.97) <0.001
Emotional stability 0.97 (0.94–0.99) 0.013
Openness 1.00 (0.97–1.03) 0.938
a Logistic regression analyses were adjusted for age, sex and education level
Bold data reflect significant findings
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and type 2 diabetes. First, the vascular depression hy-
pothesis may be especially relevant in type 2 diabetes,
since diabetes is accompanied by abundant (cardio-)vas-
cular disease. This hypothesis postulates that cerebral
small vessel lesions can lead to depressive symptoms via
damage to deep and frontal brain structures that are in-
volved in mood regulation [54, 55]. Only few longitu-
dinal studies evaluated the association between early
vascular changes and depression, and found a positive
association between markers of cerebral small vessel dis-
ease and levels of depressive symptoms and/or recurrent
depression [56–58]. In addition, higher levels of arterial
stiffening, an early phenomenon in the development of
cardiovascular disease which is accelerated in type 2 dia-
betes, were found to be slightly higher in individuals
with depression [59, 60]. Second, systemic low-grade in-
flammation is a key phenomenon in the development of
cardiovascular disease [61], a common complication of
type 2 diabetes, and also plays a role in the etiology of
depression [62]. The inflammatory pathway is likely to
involve endothelial dysfunction and oxidative stress, and
markers of these processes have been related to depres-
sion [63–66] and are known risk markers for type 2 dia-
betes [67, 68]. However, studies that specifically focus on
this topic in relation to depression and type 2 diabetes
remain scarce [69]. Third, blood glucose levels them-
selves may be a compelling regulator for mood states as
well. In particular, prolonged hyperglycemia or
hypoglycemia are able to induce negative emotional
states in type 2 diabetes [70]. The brain is particularly
vulnerable to fluctuations in plasma glucose levels, since
neurons do not possess an active glucose transporter.
This means that high plasma glucose levels have a direct
effect on intraneuronal glucose levels, which may result
in the induction of oxidative stress via the polyol path-
way, enhanced formation of advanced glycation endpro-
ducts (AGEs) and subsequent neuronal damage [71–73].
Lifestyle and medication use
Lifestyle factors, such as obesity, physical inactivity,
smoking, alcohol abuse and poor diet are well known
risk factors for the development of type 2 diabetes [50,
74]. At the same time lifestyle improvements, including
weight reduction and increased physical activity, are im-
portant aspects of diabetes management [75]. Most life-
style factors are related to depression as well, which
warrants their evaluation when examining the associ-
ation between depression and adverse health outcomes
in type 2 diabetes.
The long-term use of anti-depressants may provide a
potential mechanism in the development of type 2 dia-
betes. A meta-analysis of both cross-sectional and longi-
tudinal studies in depressive patients without diabetes
showed a 50 % increased risk of type 2 diabetes after
long-term use of antidepressants, which was not fully
explained by weight gain associated with anti-depressant
use [76].
Limitations
Due to the cross-sectional design of this study, it is not
possible to draw any conclusion regarding causality.
Carefully analyzing longitudinal data is the best alterna-
tive, and The Maastricht Study aims to fulfill this need
in the near future. We were not able to demonstrate a
significant differences in the prevalence of depressive
disorder between individuals with or without type 2 dia-
betes, while a difference was observed for depressive
symptoms. We expect that this is due to a relatively low
power, caused by the relatively low number of cases in
the diabetes group. In addition, due to the limited num-
ber of participants and the descriptive and exploratory
nature of this study, we did not control our analyses for
multiple covariates. While the inclusion of this study is
ongoing, we expect to be able to present fully adjusted
analyses in a larger study sample in due time.
Future research
The potential explanations for the association between
psychological distress, type 2 diabetes and adverse health
outcomes described here are not exclusive; the relation-
ship is likely to be multifactorial. Clearly, the psycho-
social, biological and lifestyle mechanisms that may
explain the high co-occurrence of type 2 diabetes and
psychological distress needs further research. Moreover,
most of the above mentioned studies were based on
cross-sectional data and conclude that longitudinal stud-
ies are needed to truly test the various hypotheses, as we
intend to do within The Maastricht Study.
Within the framework of The Maastricht Study, a
well-defined large and innovative population-based co-
hort study characterized by deep phenotyping, we aim to
improve our knowledge on these complex associations.
In specific, we aim to address the role of glucose metab-
olism and micro- and macrovascular complications on
the development and recurrence of depression and vice
versa. Furthermore, we aim to investigate the biological
and behavioral mechanisms that may underlie these as-
sociations. Finally, the potential added value of anxiety
and personality in the association of psychological vari-
ables with type 2 diabetes needs further study.
Conclusions
Our first exploratory results of The Maastricht Study
show a high prevalence of depression, anxiety and Type
D personality in type 2 diabetes, supporting the clinical
importance of the research aims within The Maastricht
Study.
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